Related to $3.25B Tysabri Deal a Win-Win for Biogen Idec, Elan

• Biogen Idec Ups Acquisition Price for Facet by 21%
  
• Genentech and Biogen Idec Report Positive Late-Stage Data with RA Therapy
  
• Lundbeck to Evaluate to-BBB's Technology for Delivering CNS-Disease Antibodies across the Blood-Brain Barrier
  
• Investigators Discover How Key Protein Leads to Neurodegenerative Diseases
  
• University of Florida Receives $15M, and Berkeley Lab Obtains $12.8M in ARRA Funding
  
• Acorda Obtains FDA Nod for Oral Drug that Improves Walking in MS Patients
  
• Biogen Idec Takes Over Development of Hemophilia Therapies in Deal with Swedish Orphan Biovitrum
  
• Genentech and UCSF’s Small Molecule Discovery Center Ink Deal Targeting Neurodegenerative Diseases
  
• FDA Grants New Approval for Rituxan in CD20-Positive CLL
  
• Roche and Biogen Idec Put the Brakes on Development of Ocrelizumab in RA
  
• Fast Forward and JDRF Team Up with Axxam for MS and Diabetes Treatments
  
• Biovail to Pay Cortex $10M for Ampakine Compounds against Respiratory Depression
  
• AVEO Earns $5M Milestone from Biogen Idec as Part of ErbB3 Antibody Collaboration
  
• Evotec Wins €1.5M in German Federal Funding to Take H3 Receptor Blocker into Clinic
  
• AstraZeneca to Pay $520M Settlement in Seroquel Lawsuit
  
• TPP Raises £9.6M to Build Preclinical Pipeline
  
• Santhera Shares Drop 35% as Friedreich Ataxia Drug Fails in Phase III
  
• NeuroTherapeutics Scores $43M in Series B Financing Round
  
• The Status of U.S. and European Government Funding for Synthetic Biology
  
• Pharnext Raises €4.8M to Progress Pipeline of Repositioned Drugs